IL296550A - Anti-ceramide antibodies - Google Patents

Anti-ceramide antibodies

Info

Publication number
IL296550A
IL296550A IL296550A IL29655022A IL296550A IL 296550 A IL296550 A IL 296550A IL 296550 A IL296550 A IL 296550A IL 29655022 A IL29655022 A IL 29655022A IL 296550 A IL296550 A IL 296550A
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
antigen
binding fragment
Prior art date
Application number
IL296550A
Other languages
English (en)
Hebrew (he)
Original Assignee
Memorial Sloan Kettering Cancer Center
Ceram Holding Llc
Kolesnick Richard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Ceram Holding Llc, Kolesnick Richard filed Critical Memorial Sloan Kettering Cancer Center
Publication of IL296550A publication Critical patent/IL296550A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL296550A 2020-03-18 2021-03-18 Anti-ceramide antibodies IL296550A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991232P 2020-03-18 2020-03-18
PCT/US2021/022914 WO2021188770A1 (en) 2020-03-18 2021-03-18 Anti-ceramide antibodies

Publications (1)

Publication Number Publication Date
IL296550A true IL296550A (en) 2022-11-01

Family

ID=77771401

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296550A IL296550A (en) 2020-03-18 2021-03-18 Anti-ceramide antibodies

Country Status (11)

Country Link
US (1) US12655229B2 (cg-RX-API-DMAC10.html)
EP (1) EP4121110B1 (cg-RX-API-DMAC10.html)
JP (2) JP7809067B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230031814A (cg-RX-API-DMAC10.html)
CN (1) CN115811987A (cg-RX-API-DMAC10.html)
AU (1) AU2021236669A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018682A2 (cg-RX-API-DMAC10.html)
CA (1) CA3172201A1 (cg-RX-API-DMAC10.html)
IL (1) IL296550A (cg-RX-API-DMAC10.html)
MX (1) MX2022011591A (cg-RX-API-DMAC10.html)
WO (1) WO2021188770A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201700787XA (en) 2014-08-07 2017-02-27 Sloan Kettering Inst Cancer Anti-ceramide antibodies
BR112023018758A2 (pt) * 2021-03-16 2023-11-28 Univ Michigan State Intensificação de cicatrização de ferida com anticorpos anticeramida

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
CA2398466A1 (en) 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
EP2328615A2 (en) * 2008-08-20 2011-06-08 Centocor Ortho Biotech Inc. Engineered anti-il-13 antibodies, compositions, methods and uses
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US9833949B2 (en) 2011-08-29 2017-12-05 Impossible Objects, Inc. Apparatus for fabricating three-dimensional printed composites
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
SG11201700787XA (en) * 2014-08-07 2017-02-27 Sloan Kettering Inst Cancer Anti-ceramide antibodies
CA3081058C (en) * 2015-01-16 2024-02-20 Academia Sinica Linker units and their uses in configuring pharmaceutical molecules
EP3559045A4 (en) * 2016-12-23 2020-08-19 REMD Biotherapeutics, Inc. IMMUNOTHERAPY USING ANTIBODIES THAT BIND TO A TIMED DEATH LIGAND 1 (PD-L1)
PL3618842T3 (pl) * 2017-05-01 2024-02-19 Juno Therapeutics, Inc. Kombinacja terapii komórkowej i związku immunomodulującego
WO2019237035A1 (en) * 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
BR112023018758A2 (pt) * 2021-03-16 2023-11-28 Univ Michigan State Intensificação de cicatrização de ferida com anticorpos anticeramida

Also Published As

Publication number Publication date
CA3172201A1 (en) 2021-09-23
JP2026104852A (ja) 2026-06-25
JP2023534779A (ja) 2023-08-14
MX2022011591A (es) 2023-03-06
JP7809067B2 (ja) 2026-01-30
US12655229B2 (en) 2026-06-16
KR20230031814A (ko) 2023-03-07
CN115811987A (zh) 2023-03-17
US20230167197A1 (en) 2023-06-01
BR112022018682A2 (pt) 2023-02-14
AU2021236669A1 (en) 2022-11-10
EP4121110A4 (en) 2024-06-12
WO2021188770A1 (en) 2021-09-23
EP4121110A1 (en) 2023-01-25
EP4121110B1 (en) 2026-05-27

Similar Documents

Publication Publication Date Title
IL323322A (en) Bispecific antibody constructs that bind to target cell surface antigen and cd3 epsilon chain, compositions containing them and uses thereof
IL270239B2 (en) Pharmaceutical composition containing bispecific antibody constructs for improved storage and delivery
IL313507A (en) Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
IL260920B (en) Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
IL321314A (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
IL264970B1 (en) ANTI-TIM-3 antibodies and their use
IL263223B (en) Antibodies against cd40 and their uses
IL297977A (en) sars-cov-2 antibodies and methods for selecting and using them
IL257062B (en) New anti-pd-1 antibodies
NZ591922A (en) High affinity human antibodies to human il-4 receptor
IL322389A (en) Antibodies against CD155 and their uses
IL262588B1 (en) Humanized anti-basigin antibodies and the use thereof
IL281351B1 (en) Enhanced anti-flt3 antigen-binding proteins
IL320488A (en) Anti-cd16a antibody and application thereof
IL297269A (en) Anti-flt3 antibodies and compositions
IL298825A (en) ANTI-CTLA-4 binding proteins and methods of using them
IL302586A (en) Polypeptide selectively binds to CLDN6 and CD3
JP7809067B2 (ja) 抗セラミド抗体
IL299931B1 (en) Anti-pvrig protein antibody or antibody fragment and use thereof
CN116438198A (zh) 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体
IL324231A (en) T cell engager masking molecules
IL294714A (en) Anti-nkp30 antibodies and methods of use
TW202440643A (zh) 抗人類ｃｘ３ｃｒ１抗體
IL322877A (en) Multispecific antibodies against 6cldn and 3cd and methods of use
IL322940A (en) Multivalent anti-spike protein binding molecules and their uses